Pitavastatin — Discount Pricing

Other medications in Heart & Cardiovascular

• Pravastatin
• Propafenone
• Quinapril
• Ramipril
• Ranolazine
• Riociguat
• Rivaroxaban
• Rosuvastatin

About Pitavastatin

Pitavastatin is a powerful medication prescribed to help manage high cholesterol, a key factor in heart disease. For many, the cost of essential medications like pitavastatin can be a significant barrier. TheDrugClub is dedicated to making vital prescriptions accessible, offering our members incredible savings and convenience, including $0 co-pays on eligible medications.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Pitavastatin is approved for (FDA label)

Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: • Adults with primary hyperlipidemia. • Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). Pitavastatin tablets are a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: ( 1 ) • Adults with primary hyperlipidemia. • Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).

Source: Read the full FDA label on DailyMed. Label effective date: August 15, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Pitavastatin (FDA label)

Pitavastatin Tablets are available containing 1.045 mg, 2.090 mg or 4.180 mg of pitavastatin calcium equivalent to 1 mg, 2 mg or 4 mg of pitavastatin, respectively. • The 1 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with M on one side of the tablet and PU1 on the other side. • The 2 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with M on one side of the tablet and PU2 on the other side. • The 4 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with M on one side of the tablet and PU4 on the other side.

Source: FDA prescribing information (DailyMed). Set ID: 26b5e5e8-45cd-4a98-9af4-2d04c1130881. SPL document ID: 44bb6612-917c-4457-952a-5751ea607867. Label effective date: August 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Pitavastatin (FDA label)

The following serious adverse reactions are discussed in other sections of the labeling: • Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.1) ] • Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions (5.2) ] • Hepatic Dysfunction [see Warnings and Precautions (5.3) ] • Increases in HbA1c and Fasting Serum Glucose Levels [see Warnings and Precautions (5.4) ] The most frequent adverse reactions (rate ≥ 2%) were myalgia, constipation, diarrhea, back pain, and pain in extremity. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of one drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse Reactions in Adults with Primary Hyperlipidemia In 10 controlled clinical studies and 4 subsequent open-label extension studies, 3,291 adult patients with primary hyperlipidemia were administered pitavastatin tablets 1 mg to 4 mg daily. The mean continuous exposure of pitavastatin (1 mg to 4 mg) was 36.7 weeks (median 51.1 weeks). The mean age of the patients was 60.9 years (range; 18 years–89 years) and 52% were females. Approximately 93% of the patients were White, 7% were Asian/Indian, 0.2% were African American and 0.3% were Hispanic and other. In controlled clinical studies and their open-label extensions, 3.9% (1 mg), 3.3% (2 mg), and 3.7% (4 mg) of pitavastatin tablets-treated patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: elevated creatine phosphokinase (0.6% on 4 mg) and myalgia (0.5% on 4 mg).

Source: FDA prescribing information (DailyMed). Set ID: 26b5e5e8-45cd-4a98-9af4-2d04c1130881. SPL document ID: 44bb6612-917c-4457-952a-5751ea607867. Label effective date: August 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.